Common antibiotic is NOT effective at preventing symptoms of COVID-19 in patients with mild cases 
Five COVID-19 patients being treated with azithromycin were hospitalized compared to no patients in the placebo group, a new study from the University of California, San Francisco found. (Source: the Mail online | Health)
Source: the Mail online | Health - July 19, 2021 Category: Consumer Health News Source Type: news

Azithromycin no more effective against COVID-19 than placebo: Study
The research, published in the Journal of the American Medical Association, included 263 participants who all tested positive for SARS-CoV-2, the virus which causes COVID-19, within seven days before entering the study. (Source: The Economic Times)
Source: The Economic Times - July 19, 2021 Category: Consumer Health News Source Type: news

COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191], (updated 3rd June 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily 3 June 2021 new recommendations on azithromycin to treat COVID-19 added (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 16, 2021 Category: Consumer Health News Source Type: news

Common COVID-19 antibiotic no more effective than placebo
(University of California - San Francisco) A UC San Francisco study has found that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients, and may increase their chance of hospitalization, despite widespread prescription of the antibiotic for the disease. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 16, 2021 Category: Infectious Diseases Source Type: news

Covid first wave led to increase in antibiotic misuse in India: Study
The researchers at Washington University in the US estimated that Covid-19 likely contributed to 216.4 million excess doses of antibiotics and 38 million more doses of azithromycin in adults from June 2020 through September 2020, a period of peak Covid-19 activity in India. (Source: The Economic Times)
Source: The Economic Times - July 2, 2021 Category: Consumer Health News Source Type: news

Doxycycline Trumps Azithromycin for Asymptomatic Rectal Chlamydia Doxycycline Trumps Azithromycin for Asymptomatic Rectal Chlamydia
A 1-week course of doxycycline proved to be better than single-dose azithromycin.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 30, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

What Types of New Therapies are Available for Cystic Fibrosis?
Discussion Cystic fibrosis (CF) was identified in 1938 by Dr. Dorothy Andersen who described 49 patients with pancreatic insufficiency. Since that time significant achievements in the knowledge about the disease and treatments for patients have changed the mortality from a few months to patients living into middle adulthood or even later. Quality of life for patients and their families and friends has also markedly improved. CF is the classic Mendelian autosomal recessive genetic disorder which is a worldwide disorder but affects people of north European ancestry more often where the main mutation is more common. There are...
Source: PediatricEducation.org - June 28, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Most drugs for treating adult Covid patients not recommended for kids: Government guidelines
About the treatment of children, the guidelines by the Union Health Ministry said most drugs used in adults such as ivermectin, hydroxychloroquine, favipiravir and antibiotics such as doxycycline or azithromycin have not been tested on children for prevention or treatment of Covid infection among them. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 16, 2021 Category: Pharmaceuticals Source Type: news

Managing COVID-19 [NG191], NICE (updated 3rd June 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily. On 3 June 2021 we added new recommendations on azithromycin to treat COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 3, 2021 Category: Consumer Health News Source Type: news

COVID-19 Prolongs QT Interval Independent of Other Factors COVID-19 Prolongs QT Interval Independent of Other Factors
COVID-19 infection can prolong corrected QTc in hospitalized patients, even in the absence of hydroxychloroquine and azithromycin treatment.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 26, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial , The Lancet
Findings from the PRINCIPLE platform trial show azithromycin did not improve in median time to self-reported recovery (estimated benefit 0.94 days; 95% Bayesian credibility interval −0.56 to 2.43) in this population, when compared to usual care ± other interventions. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 8, 2021 Category: Consumer Health News Source Type: news

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet
RCT (7,763 included in the assessment of azithromycin) found no significant difference for 10 days of azithromycin vs usual care for mortality at 28 days (22% for both, p=0.50), hospital stay (10 days vs 11 days) or the proportion discharged alive at 28 days (RR 1.04, p=0.19). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 4, 2021 Category: Consumer Health News Source Type: news

COVID-19 Therapeutic Alert - Antimicrobials (azithromycin and doxycycline) Not Beneficial in the Management of COVID-19 (SARS-CoV-2) Positive Patients, MHRA
Azithromycin and doxycycline should NOT be used in the management of confirmed or suspected COVID-19 infection within primary care, and azithromycin should not be used in hospitalised patients, unless there are additional indications for which use remains appropriate. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 1, 2021 Category: Consumer Health News Source Type: news

PRINCIPLE trial finds no benefit from antibiotics, azithromycin and doxycycline for COVID-19 patients, NIHR
A NIHR-supported study investigating potential COVID-19 treatments that might be suitable for patients in the community has found that the commonly used antibiotics, azithromycin and doxycycline, do not reduce recovery time for patients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 25, 2021 Category: Consumer Health News Source Type: news

Super gonorrhea could be fueled by antibiotic use amid the pandemic
A WHO spokesperson told The Sun that the use of azithromycin in misguided attempts to treat coronavirus may be encouraging the STI to become resistant to the common antibiotic. (Source: the Mail online | Health)
Source: the Mail online | Health - December 29, 2020 Category: Consumer Health News Source Type: news